- Home
- KLTO vs CDT Comparison
KLTO vs CDT Comparison
Compare KLTO & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLTO
- CDT
- Stock Information
- Founded
- KLTO 2019
- CDT 2019
- Country
- KLTO United States
- CDT United States
- Employees
- KLTO N/A
- CDT N/A
- Industry
- KLTO
- CDT Biotechnology: Pharmaceutical Preparations
- Sector
- KLTO
- CDT Health Care
- Exchange
- KLTO NYSE
- CDT Nasdaq
- Market Cap
- KLTO 9.8M
- CDT 11.1M
- IPO Year
- KLTO N/A
- CDT N/A
- Fundamental
- Price
- KLTO $0.38
- CDT $1.15
- Analyst Decision
- KLTO
- CDT
- Analyst Count
- KLTO 0
- CDT 0
- Target Price
- KLTO N/A
- CDT N/A
- AVG Volume (30 Days)
- KLTO 185.8K
- CDT 8.8M
- Earning Date
- KLTO 03-04-2025
- CDT 03-04-2025
- Dividend Yield
- KLTO N/A
- CDT N/A
- EPS Growth
- KLTO N/A
- CDT N/A
- EPS
- KLTO N/A
- CDT N/A
- Revenue
- KLTO N/A
- CDT N/A
- Revenue This Year
- KLTO N/A
- CDT N/A
- Revenue Next Year
- KLTO N/A
- CDT N/A
- P/E Ratio
- KLTO N/A
- CDT N/A
- Revenue Growth
- KLTO N/A
- CDT N/A
- 52 Week Low
- KLTO $0.26
- CDT $1.13
- 52 Week High
- KLTO $13.10
- CDT $392.00
- Technical
- Relative Strength Index (RSI)
- KLTO N/A
- CDT 31.53
- Support Level
- KLTO N/A
- CDT $1.60
- Resistance Level
- KLTO N/A
- CDT $3.70
- Average True Range (ATR)
- KLTO 0.00
- CDT 0.44
- MACD
- KLTO 0.00
- CDT 0.09
- Stochastic Oscillator
- KLTO 0.00
- CDT 0.78
About KLTO KLOTHO NEUROSCIENCES INC
Klotho Neurosciences Inc is in the development of patented, novel disease-modifying technologies targeting the brain and central nervous system (CNS) that are seen as key developments in treating neurodegenerative and age-related disorders.
About CDT Conduit Pharmaceuticals Inc.
Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being, prioritized by leading biopharmaceutical companies in order to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready in autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.